Radiation and Melanoma: Where Are We Now?
- PMID: 38822928
- DOI: 10.1007/s11912-024-01557-y
Radiation and Melanoma: Where Are We Now?
Abstract
Purpose of review: This review summarizes the current role of radiotherapy for the treatment of cutaneous melanoma in the definitive, adjuvant, and palliative settings, and combinations with immunotherapy and targeted therapies.
Recent findings: Definitive radiotherapy may be considered for lentigo maligna if surgery would be disfiguring. High risk, resected melanoma may be treated with adjuvant radiotherapy, but the role is poorly defined since the advent of effective systemic therapies. For patients with metastatic disease, immunotherapy and targeted therapies can be delivered safely in tandem with radiotherapy to improve outcomes. Radiotherapy and modern systemic therapies act in concert to improve outcomes, especially in the metastatic setting. Further prospective data is needed to guide the use of definitive radiotherapy for lentigo maligna and adjuvant radiotherapy for high-risk melanoma in the immunotherapy era. Current evidence does not support an abscopal response or at least identify the conditions necessary to reliably produce one with combinations of radiation and immunotherapy.
Keywords: Immunotherapy; Melanoma; Radiotherapy; Stereotactic body radiotherapy; Stereotactic radiosurgery; Targeted therapy.
© 2024. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.
Similar articles
-
Gamma Knife Radiosurgery and Immunotherapy as Primary Treatment for a Malignant Tumor of the Cranial Base Beginning as Lentigo Maligna: A Case Report.Pract Radiat Oncol. 2019 Nov;9(6):e608-e612. doi: 10.1016/j.prro.2019.05.010. Epub 2019 May 23. Pract Radiat Oncol. 2019. PMID: 31129314 No abstract available.
-
Fractionated radiotherapy of lentigo maligna and lentigo maligna melanoma in 64 patients.J Am Acad Dermatol. 2000 Sep;43(3):477-82. doi: 10.1067/mjd.2000.106241. J Am Acad Dermatol. 2000. PMID: 10954659 Clinical Trial.
-
Immunocryosurgery as monotherapy for lentigo maligna or combined with surgical excision for lentigo maligna melanoma.J Dermatol. 2018 May;45(5):564-570. doi: 10.1111/1346-8138.14248. Epub 2018 Feb 11. J Dermatol. 2018. PMID: 29430695
-
Lentigo maligna : prognosis and treatment options.Am J Clin Dermatol. 2005;6(3):151-64. doi: 10.2165/00128071-200506030-00002. Am J Clin Dermatol. 2005. PMID: 15943492 Review.
-
[Dubreuilh melanoma(lentigo maligna melanoma)].Ann Dermatol Venereol. 2001 Feb;128(2):172-6. Ann Dermatol Venereol. 2001. PMID: 11275603 Review. French. No abstract available.
Cited by
-
Cutaneous Melanoma: An Overview of Physiological and Therapeutic Aspects and Biotechnological Use of Serine Protease Inhibitors.Molecules. 2024 Aug 16;29(16):3891. doi: 10.3390/molecules29163891. Molecules. 2024. PMID: 39202970 Free PMC article. Review.
-
Therapeutic Treatment Options for In-Transit Metastases from Melanoma.Cancers (Basel). 2024 Sep 3;16(17):3065. doi: 10.3390/cancers16173065. Cancers (Basel). 2024. PMID: 39272923 Free PMC article. Review.
References
Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance
-
- Wolchok JD, Chiarion-Sileni V, Gonzalez R, Grob JJ, Rutkowski P, Lao CD, et al. Long-Term Outcomes With Nivolumab Plus Ipilimumab or Nivolumab Alone Versus Ipilimumab in Patients With Advanced Melanoma. J Clin Oncol. 2022;40(2):127–37. A phase 3 study showing a 57% melanoma-specific survival rate at 5 years with D-ICI for stage III-IV melanoma patients, much improved from historical outcomes.
-
- Scott GA. Differential diagnosis in dermatopathology III. Arch Dermatol. 1993;129(6):804. - DOI
-
- McKenna JK, Florell SR, Goldman GD, Bowen GM. Lentigo maligna/lentigo maligna melanoma: current state of diagnosis and treatment. Dermatol Surg. 2006;32(4):493–504. - PubMed
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical
Research Materials